Medical oncology is an internal medicine subspecialty dedicated to the diagnosis, treatment, and long-term management of cancer through systemic therapies such as chemotherapy, molecularly targeted therapy, immunotherapy, and investigational therapy. Medical oncologists are responsible for assessing disease stage and prognosis, formulating individualized treatment plans, and managing adverse effects while also providing survivorship care. We collaborate closely with surgeons, radiation oncologists, pathologists, nurses, pharmacists, and social workers to deliver comprehensive, multidisciplinary cancer care. In addition, we play a leading role in the design and conduct of clinical trials, thereby contributing to the implementation of novel therapies. Medical oncology also emphasizes research—particularly translational research—and education, establishing its position as a discipline that advances science, clinical practice, and training as three inseparable pillars.
Clinical Practice
Our department provides systemic therapy for a wide range of solid tumors, including gastrointestinal, breast, lung, gynecologic, and genitourinary cancers. Our practice incorporates cutting-edge treatments such as molecularly targeted agents, immune checkpoint inhibitors, and antibody-drug conjugates (ADCs). We also emphasize cancer genomic medicine and supportive care—including pain management, antiemetic therapy, and interventions for cancer cachexia—to improve patients’ quality of life. Through collaboration with palliative care and genetic medicine services, as well as partnerships with regional medical institutions, we deliver state-of-the-art treatments broadly and equitably.
Research Activities
Our research activities span three domains: clinical, translational, and basic science.
Clinical Research
• Active participation in multicenter phase I–III clinical trials
• Development of personalized medicine strategies based on biomarkers
• Exploration of novel therapies for rare and refractory tumors
• Evaluation of efficacy and safety of immunotherapies, targeted agents, and ADCs
Translational Research
• Identification of predictive biomarkers through analysis of tumor tissues and circulating factors
• Integration of genomic data with clinical outcomes
• Investigation of the tumor microenvironment, including immune cell infiltration and cytokine networks
• Elucidation of drug resistance mechanisms and development of strategies to overcome them
Basic Research
• Molecular studies of cancer-related genetic alterations and therapeutic sensitivity
• Investigation of tumor progression mechanisms mediated by miRNAs and epigenomic changes
• Pathophysiological research on cancer cachexia and tumor metabolism
The outcomes of these research activities have been disseminated in international peer-reviewed journals and presented at scientific meetings worldwide, contributing to the advancement of medical oncology and its clinical applications. Moreover, physician-initiated trials and academic–industry collaborations have generated that directly foster the development and clinical implementation of innovative therapies.
|
